ResMed (RMD) Upgraded to Buy: What Does It Mean for the Stock?
ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions
ResMed introduces digital and personalized solutions designed to improve sleep health.
ResMed: Growing Returns With Continuous Acquisitions Led To A Margin Of Safety
ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed results, with improvements in gross profitability and asset turnover but a longer cash conversion cycle. But there were improving returns. The company is financially sound. There is a margin of safety if you assume that there would be another major acquisition next year.
S&P 500 Gains and Losses Today: ResMed Drops as Weight-Loss Drugs Threaten Demand
Major U.S. equities indexes ended lower on Wednesday after the Federal Reserve reduced its benchmark interest rate by half a percentage point. Central bank policymakers opted for an aggressive rate cut as the focus shifts toward economic growth and the employment market following a multi-year campaign to fight inflation.
Why ResMed Stock Tumbled by 5% Today
An analyst downgraded his recommendation on the medical device specialist. He now feels investors should avoid it.
Why ResMed's Rally Is Just Getting Started
ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns. The company's AirSense 11 platform and myAir app enhance patient engagement and efficiency, contributing to higher margins and adoption rates. Despite a low dividend yield and recent insider sales, ResMed's strong balance sheet and market potential offer substantial upside for patient long-term investors.
Reasons to Retain ResMed Stock in Your Portfolio for Now
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ResMed Inc. investment
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
ResMed Shares Breathing Life into Big Money Portfolios
Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.
